Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: Pooled findings from three randomized phase III trials

Diabetes, Obesity and Metabolism

Volumn 17, Issue 6, 2015, Pages 560-565

  Henry, R R ^a   Buse, J B ^b   Wu, H ^c   Durrwell, L ^d   Mingrino, R ^d   Jaekel, K ^d   El Azzouzi, B ^d   Andjelkovic, M ^d   Herz, M ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c China Energy Technology Holdings Ltd   (China)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Glycaemic control; Lipid lowering therapy; Metformin; PPAR gamma agonist; Sulphonylureas; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ALEGLITAZAR; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; SULFONYLUREA; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LIPID; OXAZOLE DERIVATIVE; SULFONYLUREA DERIVATIVE; THIOPHENE DERIVATIVE;

ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLECYSTITIS; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSESSMENT; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED CANCER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HERPES ZOSTER; HOMEOSTATIC MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS TUMOR; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; THYROID CARCINOMA; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; WEIGHT CHANGE; ANALYSIS; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPIDS; MALE; METFORMIN; MIDDLE AGED; OXAZOLES; SULFONYLUREA COMPOUNDS; THIOPHENES;

EID: 84928430152     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12455     Document Type: Article

References (16)

1. UKPDS Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
2. UKPDS Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865.
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
4. Dietz M, Mohr P, Kuhn B etal. Comparative molecular profiling of the PPARalpha/gamma activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. Chem Med Chem 2012; 7: 1101-1111.
5. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009; 374: 126-135.
6. Lincoff AM, Tardif JC, Schwartz GG etal. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio Randomized Clinical Trial. JAMA 2014; 311: 1515-1525.
7. Ruilope L, Hanefeld M, Lincoff AM etal. Effects of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study. BMC Nephrol 2014; 15: 180.
8. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
10. Miyazaki Y, Mahankali A, Matsuda M etal. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784-2791.
11. Kahn SE, Haffner SM, Heise MA etal. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
12. Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus-a pooled meta-analysis of randomized placebo-controlled clinical trials. Int J Cardiol 2010; 141: 157-166.
13. Malmberg K, Hanefeld M, Ruilope L etal. Effects of aleglitazar on cardiovascular risk factors in patients with stage 3 chronic kidney disease and type II diabetes. J Am Coll Cardiol 2013; 61(10_S); DOI: 10.1016/S0735-1097(13)61173-0.
14. Herz M, Gaspari F, Perico N etal. Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. Int J Cardiol 2011; 151: 136-142.
15. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 2003; 115(Suppl. 8A): 42S-48S.
16. Lipscombe J, Lewis GF, Cattran D, Bargman JM. Deterioration in renal function associated with fibrate therapy. Clin Nephrol 2001; 55: 39-44.